POSA166 Cost-Effectiveness of Using Dapagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction: A Pharmacoeconomic Model Analysis

Abstract

Authors

Y Cavusoglu Ö Demir M Dinc A Ozsoy A Erdogan S Özer

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×